S-1, A NOVEL ORAL FLUOROPYRIMIDINE, WHEN COMBINED WITH CISPLATIN, DEMONSTRATES SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL OF ADVANCED GASTRIC CANCER PATIENTS OVER S-1 ALONE

Menu

Media Room Menu

S-1, A NOVEL ORAL FLUOROPYRIMIDINE, WHEN COMBINED WITH CISPLATIN, DEMONSTRATES SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL OF ADVANCED GASTRIC CANCER PATIENTS OVER S-1 ALONE

Print
Email page
RSS

Click Here for Full Release

39 KB

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.